경피 피부 패치 시장 : 시장 규모, 점유율 및 동향 분석 보고서 - 유형별, 용도별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Transdermal Skin Patches Market Size, Share & Trends Analysis Report By Type (Multi-layer Drug-in-Adhesive), By Application (Pain Relief), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,845,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,332,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,305,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

경피 피부 패치 시장 요약

세계의 경피 피부 패치 시장 규모는 2024년 62억 달러로 평가되었고, 2030년까지 95억 5,000만 달러에 이를 것으로 예측됩니다.

2025-2030년 CAGR 7.6%로 성장할 것으로 예측됩니다. 본 시장의 성장 요인으로는 심혈관 질환, 당뇨병, 만성 통증 등의 만성 질환 증가, 저침습성 치료법에 대한 소비자 선호의 고조, 세계적인 고령화, 경피 약물 전달 기술의 발전 등을 들 수 있습니다.

경피 피부 패치는 경구제나 주사제에 비해 비침습적이고 편리한 약제 관리 수단을 제공합니다. 따라서 환자는 처방대로 복약할 가능성이 높아 경구약에 비해 위장계의 부작용도 경감됩니다. 사용의 간편함 및 장기간에 걸쳐 안정적인 약물 방출 특성으로 인해, 경피 피부 패치는 특히 만성 질환의 관리에서 높은 수요가 예상됩니다.

세계적인 만성 질환이 증가함에 따라 업계는 현저한 성장을 이루고 있습니다. 2024년 2월 시점에서 미국 질병 예방관리센터(CDC)의 추계에 의하면, 미국에는 암, 심장병, 비만, 당뇨병, 고혈압 등의 주요 만성 질환을 적어도 1개 가지고 있는 환자가 1억 2,900만 명 존재합니다. 만성 통증의 가장 흔한 치료법은 환자가 매일 진통제를 복용하는 것입니다. 경피 피부 패치는 장시간에 걸쳐 약물을 조절하고 방출함으로써 복약 준수율을 향상시키기 때문에 이러한 상황에서 효능을 나타냅니다. 예를 들어, 펜타닐 경피 피부 패치는 만성 통증 관리에 승인되었으며, 72시간 동안 펜타닐을 지속적으로 방출함으로써 저용량의 통증 완화를 실현하고 투여 빈도를 감소시킵니다.

마이크로니들, 이온토폴리시스, 침투 촉진제 등의 혁신 기술은 경피 약물 전달의 정세를 넓혀 고분자 화합물이나 생물학적 제제의 투여에 새로운 길을 열고 있습니다. 마이크로니들 패치는 피부에 미세한 통로를 형성하고 경피 투여에 너무 큰 고분자 약물의 전달을 촉진합니다. 예를 들어, 인슐린 함유 마이크로니들 패치는 매일 주사를 대체하는 통증이 없는 인슐린 섭취 방법을 실현하여 혈당 관리 최적화에 기여합니다. 이온토폴리시스는 약한 전기 자극을 사용하여 약물을 피부에 투과시키는 새로운 혁신적인 전달 전략입니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 경피 피부 패치 시장의 변수, 동향 및 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 경피 피부 패치 시장 : 유형별 추정 및 동향 분석

• 부문 대시보드
• 경피 피부 패치 시장 : 유형별 변동 분석(10억 달러, 2018년 및 2030년)
• 경피 피부 패치 시장 : 제품별 전망
• 시장 규모와 예측 및 동향 분석(2018-2030년)
• 단층 약제내 접착제
• 다층 약제내 접착제
• 매트릭스
• 기타 유형

제5장 경피 피부 패치 시장 : 용도별 추정 및 동향 분석

• 부문 대시보드
• 경피 피부 패치 시장 : 용도별 변동 분석
• 경피 피부 패치 시장 : 기능별 전망
• 시장 규모와 예측 및 동향 분석(2018-2030년)
• 통증 완화
• 흡연 감소 및 금연 지원
• 심혈관 질환
• 신경 질환
• 호르몬 요법
• 기타 용도

제6장 경피 피부 패치 시장 : 유통 채널별 추정 및 동향 분석

• 부문 대시보드
• 경피 피부 패치 시장 : 유통 채널별 변동 분석
• 경피 피부 패치 시장 : 유통 채널별 변동 분석(10억 달러, 2018년 및 2030년)
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 경피 피부 패치 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 및 동향 분석(2018-2030년) :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향 및 영향 분석
• 기업 및 경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석(2024년)
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Teikoku Pharma USA Inc.
  • Viatris Inc.
  • Johnson &Johnson
  • Luye Pharma Group
  • Purdue Pharma Manufacturing LP
  • Henan Lingrui Pharmaceutical Ltd
  • Samyang Biopharmaceuticals Corp.
  • Hisamitsu Pharmaceutical Co, Inc.

AJY

영문 목차

영문목차

Transdermal Skin Patches Market Summary

The global transdermal skin patches market size was valued at USD 6.20 billion in 2024 and is projected to reach USD 9.55 billion by 2030, growing at a CAGR of 7.6% from 2025 to 2030. The market is increasing due to the growing incidence of chronic diseases such as cardiovascular disease, diabetes, chronic pain, etc., the enhanced preference of consumers for less-invasive treatment options, an aging population worldwide, and the technological advancement in transdermal drug delivery methods.

Transdermal patches offer a non-invasive and convenient approach to managing drugs through oral and injectable formulations; therefore, patients are more likely to take their medications as prescribed and experience lower gastrointestinal side effects than oral medications. Due to their ease of use and consistent drug-release rates over long periods, transdermal patches are especially appealing in chronic disease state management.

The industry is experiencing notable growth because of the rise of chronic diseases across the globe. In February 2024, the Centers for Disease Control and Prevention (CDC) estimates there are 129 million people in the United States with at least one key chronic disease, such as cancer, heart disease, obesity, diabetes, and hypertension. The most common treatment for chronic pain is to have the patient take pain relief medication daily, which is not only tedious, but oral or injectable forms often have bothersome side effects and burdensome frequency of administration. Transdermal patches can show efficacy in these scenarios as they improve adherence to medication therapy through regulated medication delivery over a longer period. For example, fentanyl transdermal patches have been approved for chronic pain management and will continuously release fentanyl over 72 hours, providing low-dose relief and reducing the frequency of administration.

Innovations like microneedles, iontophoresis, and permeation enhancers have broadened the transdermal drug delivery landscape, creating new possibilities for administering large molecules and biologics. Microneedle patches generate tiny channels to the skin to enhance the delivery of large-molecule drugs that are too large to administer transdermally. For instance, a microneedle patch containing insulin allows for a pain-free way of taking insulin rather than daily needles, which may optimize control of glycemic levels. Iontophoresis is a newer, innovative delivery strategy that utilizes a small electric charge to help push drugs through the skin.

Global Transdermal Skin Patches Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global transdermal skin patches market report by type, application, distribution channel, and region:

• Type Outlook (Revenue, USD Unit, 2018 - 2030)
• Single-layer Drug-in-Adhesive
• Multi-layer Drug-in-Adhesive
• Matrix
• Other Types
• Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Pain Relief
• Smoking Reduction and Cessation Aid
• Cardiovascular Disorders
• Neurological Disorders
• Hormonal Therapy
• Other Applications
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in the Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Transdermal Skin Patches Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Increased consumer preference for minimally invasive treatment
    • 3.2.1.3. Aging global population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Skin irritation and allergic reactions
    • 3.2.2.2. Limited awareness
  • 3.2.3. Industry Analysis - Porter's
    • 3.2.3.1. Bargaining power of the suppliers
    • 3.2.3.2. Bargaining power of the buyers
    • 3.2.3.3. Threats of substitution
    • 3.2.3.4. Threats from new entrants
    • 3.2.3.5. Competitive rivalry
  • 3.2.4. PESTEL Analysis
    • 3.2.4.1. Political landscape
    • 3.2.4.2. Economic landscape
    • 3.2.4.3. Social landscape
    • 3.2.4.4. Technological landscape
    • 3.2.4.5. Environmental landscape
    • 3.2.4.6. Legal landscape

Chapter 4. Transdermal Skin Patches Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Transdermal Skin Patches Market: Type Movement Analysis, USD Billion, 2018 & 2030
• 4.3. Transdermal Skin Patches Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Single-layer Drug-in-Adhesive
  • 4.5.1. Single-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 to 2030 (USD Billion)
• 4.6. Multi-layer Drug-in-Adhesive
  • 4.6.1. Multi-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 to 2030 (USD Billion)
• 4.7. Matrix
  • 4.7.1. Matrix Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 4.8. Other Types
  • 4.8.1. Other Types Market Estimates And Forecasts, 2018 to 2030(USD Billion)

Chapter 5. Transdermal Skin Patches Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Transdermal Skin Patches Market: Application Movement Analysis
• 5.3. Transdermal Skin Patches Market by Function Outlook (USD Billion)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Pain Relief
  • 5.5.1. Pain Relief Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 5.6. Smoking Reduction and Cessation Aid
  • 5.6.1. Smoking Reduction Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 5.7. Cardiovascular Disorders
  • 5.7.1. Cardiovascular Disorders Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 5.8. Neurological Disorders
  • 5.8.1. Neurological Disorders Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 5.9. Hormonal Therapy
  • 5.9.1. Hormonal Therapy Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 5.10. Other Applications
  • 5.10.1. Other Applications Market Estimates And Forecasts, 2018 to 2030(USD Billion)

Chapter 6. Transdermal Skin Patches Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Transdermal Skin Patches Market: Distribution Channel Movement Analysis
• 6.3. Transdermal Skin Patches Market: Distribution Channel Movement Analysis, USD Billion, 2018 & 2030
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market Estimates And Forecasts, 2018 to 2030(USD Billion)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market Estimates And Forecasts, 2018 to 2030(USD Billion)

Chapter 7. Transdermal Skin Patches Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. North America Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Teva Pharmaceutical Industries Ltd
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Type benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Novartis AG
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Type benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Teikoku Pharma USA Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Viatris Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Johnson & Johnson
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Luye Pharma Group
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Purdue Pharma Manufacturing LP
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Henan Lingrui Pharmaceutical Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Samyang Biopharmaceuticals Corp.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Hisamitsu Pharmaceutical Co, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Type benchmarking
    • 8.3.11.4. Strategic initiatives

관련자료